We plan strength, balance, and aerobic exercise together.
Multi-component exercise tailored to the individual's health status is an important foundation for frailty management that maintains mobility and daily function.
OSANG SPECIALTY CENTER
Stem Cell Clinic
Easily view healthy aging and aging research
To what extent has anti-aging
stem cell research been confirmed?
Current human studies are not looking at the effects of reversing aging itself, but rather looking at mobility, strength, physical function, quality of life, and short-term safety in patients with age-related frailty. We summarized the results of external research and the remaining limitations.
external thesis×Results commentary
Easily view anti-aging stem cell research papers
Research on humans looks at aging and
physical function, not ‘rejuvenation’.
The subjects evaluated in the paper are adults with age-related frailty, not rejuvenation in healthy people. We checked whether there were any changes in walking, balance, muscle strength, fatigue, quality of life, and inflammation-related indicators, and whether there were any adverse reactions.
The content below is a simple explanation of the published external research. It is not a treatment result from Osang Neurosurgery and does not guarantee anti-aging effects or indications.
Things to know first
The basics of aging management and cell research must be viewed separately.
Currently, management of aging is based on exercise, nutrition, medication monitoring, and management of underlying diseases. Stem cell research is not a replacement for established standard anti-aging treatments.
We examine nutritional status and chronic diseases together.
We check for weight loss and nutritional deficiencies, and check the effects of diseases and medications on fatigue, dizziness, and muscle weakness.
Probability signals and established effects are different
The results of early and mid-stage clinical trials alone cannot say whether aging will be reversed, lifespan extended, or the same effects will be achieved for all people.
How to view study resultsDon't just look at the numbers,
Don't just look at the numbers,
we also look at the study design.
Because the source and dose of mesenchymal stromal cells (MSCs), number of administrations, comparison group and blinding, and follow-up period are different, study results cannot be simply compared as if they were the same treatment.
We check whether the subject meets the criteria for frailty rather than a healthy adult.
The starting point for research is different between people of the same age and frail patients with reduced walking ability and muscle strength and increased fatigue.
Ensure there was placebo and blinding
Randomization, placebo control, and blinding are important to prevent exercise intention or evaluator expectations from being mixed with the results.
See if your walking distance and test scores lead to real life changes
A separate, larger study will also need to determine whether long-term outcomes such as falls, hospitalization, and disability are reduced.
Probability signals identified in the current paper
- In some randomized trials, 6-minute walking distance and short physical function test scores improved compared to comparison groups.
- Changes were also reported in grip strength, fatigue, quality of life and some inflammation-related markers.
- No events considered serious adverse reactions related to the study product were reported in the presented clinical trials.
What cannot be concluded yet
- It has not been proven to reverse aging, lower biological age, or extend lifespan.
- It has not been determined whether it reduces actual long-term outcomes such as falls, fractures, hospitalization, disability, or death.
- Different cell sources and doses require larger studies to determine the optimal method, duration of effect, and rare long-term adverse effects.
3 randomized trials · Total 208 people · Systematic literature review · 2026
Although there were likely signals across the
three studies, they did not combine effect sizes.
This is a systematic review that collected only randomized trials targeting age-related frailty by searching the database from the inception until April 15, 2026. Meta-analysis was not performed due to differences in cell source, dose, target, and evaluation method. The 2026 Nguyen study from eBioMedicine, published after the search closed, was not included in this review.
- How many episodes have you reviewed?
- 3 randomized controlled trials
- How many people were included?
- Total 208 people
- What did you look for?
- Mobility, physical function, quality of life, inflammation, safety
- Did you calculate the results together?
- Meta-analysis was not performed due to large study differences.
Randomized controlled trials includedPart 3Bone marrow or umbilical cord tissue derived MSC research
Included studiesPart 3
Total participants includedTotal 208 peopleSize and design of each study vary.
All participants208 people
integrated effect valuenot calculatedDue to significant differences between studies, results are not combined into one number.
research 01
If you solve it easily,
You can look at the result like this.
Some trials reported signs of improvement in walking, physical function, quality of life, or inflammation-related parameters, but these were not consistently replicated across doses, time points, and endpoints. There were only three studies and their methods were different, and the review authors assessed all three trials as having some concerns about risk of bias.
Original sourceView the original text and research information
Frailty MSC randomized trial systematic reviewInternational Journal of Molecular Sciences · 2026 · 3 RCTsThe finding that no treatment-related serious adverse events were reported does not indicate that adverse events are rare or that long-term safety has been established. This does not mean that there were no serious incidents or deaths during the study period. For example, in the Phase 2b trial, there was one death in the treatment group and one death in the placebo group, but it was not determined to be related to the study product. Reductions in falls, hospitalizations, disabilities, and deaths have not yet been confirmed.
Phase 2b · 148 people administered · Randomized, double-blinded, placebo-controlled · 2026
There was a difference in the 6-minute walking distance between some dose groups at 9 months,
but the individual comparison of the highest dose at 6 months with placebo was not significant.
This is a dose-exploration study in which allogeneic MSCs derived from bone marrow from young donors were administered intravenously once to frail adults aged 70 to 85 years and compared with four dose groups and a placebo group.
- How many people participated?
- 148 people administered, 143 people modified, intention-to-treat analysis
- How did you divide it?
- Randomized to 4 dose groups or placebo group
- What did you do?
- One-time intravenous administration of 25 to 200 million bone marrow-derived allogeneic MSCs
- When did you see the results?
- 6 months for main evaluation, 9 months for additional evaluation
6-month, 6-minute walking distance · Difference between 200 million group and placebo+41.3m95% confidence interval −2.4~84.9m · p=.0635 · Individual comparisons are not statistically significant
Difference compared to placebo+41.3m
9 months 6 minutes walking distance · Difference between 200 million group and placebo+63.4m95% confidence interval 17.1~109.6m · p=.0077
Difference compared to placebo+63.4m
Grip strength and 4m walking speedno noticeable differenceNot all physical function indicators improved together
research 02
If you solve it easily,
You can look at the result like this.
Although there was a signal in the predetermined 6-month dose-response analysis, individual comparisons of the 200 million dose group and the placebo group included no difference in confidence intervals. At 9 months, there was a difference compared to placebo in the 50 million and 200 million groups, but the lasting effect cannot be confirmed with only the results at one point in time.
Original sourceView the original text and research information
Laromestrocel frailty phase 2b clinical trialCell Stem Cell · 2026 · PMID 41747733Clinical trial registration informationClinicalTrials.gov · NCT03169231Each dose group was small, with 16 people in the 200 million dose group. Dementia patients were excluded, and the gender composition of some groups was also different. NIH/NIA research funds were provided to the developer Longeveron, and many of the authors were executives, advisors, board members, or equity owners of the developer. Independent large-scale replication studies are needed.
Phase 2 · Randomization of 148 people · Administration of 147 · Randomization · Open type · Blinding of evaluators · 2026
Differences were reported in 9-month physical
function scores and gait and muscle strength.
Frail adults aged 60 to 85 years were divided into two groups. One group received umbilical cord-derived allogeneic MSCs intravenously twice at three-month intervals, and both groups used nutritional supplements.
- How many people participated?
- 148 people randomized, 147 administered (73 MSC / 74 comparison group)
- Was there a blindfold?
- Participants and medical staff are open to the public; outcome evaluators are blinded.
- What did you do?
- Umbilical cord-derived allogeneic MSC 1.5 million units/kg, twice at 3-month intervals
- When did you see the results?
- Followed for 9 months
9-month SPPB physical function score · Differences between groups+0.8 points95% confidence interval 0.3~1.3 points based on Table 3 in the main text · Internal discrepancy between +1.1 point notation in the paper summary
Difference compared to comparison group+0.8 points
9-month grip strength Differences between groups+2.7kg95% confidence interval 1.1 to 4.4 kg
Difference compared to comparison group+2.7kg
Pulmonary function and cardiac ejection fractionNo differences between groupsNot all physiological functions change together
research 03
If you solve it easily,
You can look at the result like this.
Differences between groups were reported in physical function and some life-related indicators. However, since the participants and treatment staff knew what treatment they received, and the comparison group only received nutritional supplements without placebo injection, we cannot rule out the possibility that expected effects were mixed in the results.
Original sourceView the original text and research information
Umbilical cord-derived MSC senescence phase 2 clinical trialeBioMedicine · 2026 · PMID 42019090Clinical trial registration informationClinicalTrials.gov · NCT04919135This is a single-center, open-label phase 2 study, and it is difficult to determine the durability of the effect and rare adverse reactions with only 9 months of follow-up. Changes in cellular aging-related markers also occur only at one point in time and cannot be interpreted to mean that aging has been reversed. Additionally, since anticoagulant and antihistamine prophylaxis were administered before cell administration, safety results should be interpreted under the corresponding protocol.